Effective Oral Antibiotics for Osteomyelitis

Pathogen-Specific Oral Antibiotic Options

• The Infectious Diseases Society of America recommends clindamycin 300-450 mg PO four times daily as a second-line choice for susceptible staphylococcal osteomyelitis 1
• The Infectious Diseases Society of America recommends TMP-SMX 1-2 double-strength tablets PO twice daily, often combined with rifampin, for MRSA osteomyelitis 3
• The Infectious Diseases Society of America recommends linezolid 600 mg PO twice daily for MRSA osteomyelitis when first-line agents cannot be used 1
• The Infectious Diseases Society of America recommends doxycycline with rifampin as an effective combination therapy for susceptible strains 3
• The Infectious Diseases Society of America recommends ciprofloxacin 500-750 mg PO twice daily for Enterobacteriaceae, Pseudomonas aeruginosa, and Salmonella species 1
• The Infectious Diseases Society of America recommends levofloxacin 500-750 mg PO once daily for Enterobacteriaceae and other susceptible aerobic gram-negative organisms 1
• The Infectious Diseases Society of America recommends moxifloxacin 400 mg PO once daily for Enterobacteriaceae and other susceptible gram-negative organisms 1
• The Infectious Diseases Society of America recommends metronidazole 500 mg PO three to four times daily for Bacteroides species and other susceptible anaerobes 1
• The Infectious Diseases Society of America recommends doxycycline and rifampin combination as the most commonly used regimen for brucellosis involving bone 1

Treatment Duration and Approach

• The Infectious Diseases Society of America recommends a minimum 8-week course for MRSA osteomyelitis 3
• Some experts suggest an additional 1-3 months of oral rifampin-based combination therapy for chronic infections or when debridement is not performed 3
• The Infectious Diseases Society of America recommends surgical debridement and drainage of associated soft-tissue abscesses as the mainstay of therapy and should be performed whenever feasible 3

Special Considerations

• The Infectious Diseases Society of America recommends adding rifampin (600 mg daily or 300-450 mg twice daily) to the primary antibiotic for better bone penetration and biofilm activity, but only after clearance of bacteremia to prevent resistance development 3
• The Infectious Diseases Society of America recommends using MRI with gadolinium as the imaging modality of choice for monitoring response to therapy 3
• The Infectious Diseases Society of America recommends using ESR and CRP levels to help guide response to therapy, but should be interpreted in context with clinical status 3

Antibiotic Selection Algorithm

• The Infectious Diseases Society of America recommends obtaining bone culture before starting antibiotics whenever possible 3
• The Infectious Diseases Society of America recommends selecting antibiotic based on identified pathogen and susceptibility testing, bone penetration characteristics, and patient-specific factors (allergies, renal/hepatic function) 1
• The Infectious Diseases Society of America recommends using TMP-SMX plus rifampin or linezolid for empiric therapy when MRSA is suspected 3
• The Infectious Diseases Society of America recommends using fluoroquinolone for empiric therapy when gram-negative infection is suspected 1

Common Pitfalls and Caveats

• The Infectious Diseases Society of America recommends against using fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) as monotherapy for staphylococcal osteomyelitis due to risk of resistance development 1
• The Infectious Diseases Society of America recommends against using linezolid for more than 2 weeks due to risk of myelosuppression and peripheral neuropathy 2
• The Infectious Diseases Society of America recommends always combining rifampin with another active agent to prevent emergence of resistance 2